Pharma

research deal two people shaking hands in lab

Merck opts in on Evaxian's preclinical vaccine candidate

Merck is licensing one of Evaxion’s AI platform-based vaccine candidates, offering the biotech up to $592 million for rights to the preclinical asset.

Gabrielle Masson Sep 25, 2025 7:00am

Biopharma biobucks decline, while upfront deal payments rise

Sep 24, 2025 11:30am

Cartoon of businessmen standing around a broken target

Harmony's pivotal trial flops as placebo response causes discord

Sep 24, 2025 9:35am

uniQure plans FDA push after Huntington's gene therapy trial win

Sep 24, 2025 9:20am

BMS reports phase 3 win in multiple myeloma

Sep 23, 2025 8:20am

3D Rendering futuristic robot technology development artificial intelligence

Merck inks $349M biobucks deal to apply AI to tricky targets

Sep 23, 2025 7:00am